Xcout IntelADALTA LIMITED
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases. The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens. AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
Subscribe to see ADALTA LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ADALTA LIMITED at a glance
ADALTA LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Camberwell, Australia. It is publicly listed (1AD) with a market capitalisation of $1.3M. Xcout tracks 5 named people at ADALTA LIMITED, including Tim Oldham (CEO & MANAGING DIRECTOR).
ADALTA LIMITED leadership
- Tim OldhamCEO & MANAGING DIRECTOR
- Paul MacLemanCHAIRMAN
- Cameron JonesCOMPANY SECRETARY
- Fadi DiabNON-EXECUTIVE DIRECTOR
- Michelle BurkeNON-EXECUTIVE DIRECTOR
Get ADALTA LIMITED's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ADALTA LIMITED in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access